With 0.9 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.81 million shares. The 52-week range on CDNA shows that it touched its highest point at $34.84 and its lowest point at $7.42 during that stretch. It currently has a 1-year price target of $32.38. Beta for the stock currently stands at 1.95.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDNA was down-trending over the past week, with a drop of -10.27%, but this was down by -3.88% over a month. Three-month performance surged to 3.39% while six-month performance fell -31.31%. The stock gained 170.84% in the past year, while it has gained 4.11% so far this year. A look at the trailing 12-month EPS for CDNA yields -2.70 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.41. This implies an EPS growth rate of 74.72% for this year and 44.69% for next year. EPS is expected to grow by 73.75% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.96%.
Float and Shares Shorts:
At present, 53.11 million CDNA shares are outstanding with a float of 50.23 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDNA since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.79979 being high and -$1.0283 being low. For CDNA, this leads to a yearly average estimate of -$0.895. Based on analyst estimates, the high estimate for the next quarter is $0.12 and the low estimate is $0.05. The average estimate for the next quarter is thus $0.09.
